Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.

Affecting the nervous system, immune system and other body organs, ataxia telangiectasia is characterized with uncoordinated movements of the individual suffering from this disorder. The secondary ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.

Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Hereditary hemorrhagic telangiectasia, or Osler–Weber–Rendu syndrome, is an autosomal dominant vascular disorder that affects multiple systems. It is characterized by skin and mucosal telangiectasias ...

Please provide your email address to receive an email when new articles are posted on . The NT-501 implant demonstrated positive results in two replicative phase 3 clinical trials for the treatment of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WAILEA, Hawaii —NT-501, an encapsulated cell therapy for ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment ...

IMMUNOLOGIC abnormalities, including hypogammaglobulinemia, abnormalities of gamma 1 A globulin, poor homograft rejection and structural abnormalities of the thymus gland, have recently been reported ...

An IgE deficiency was demonstrated in 11 of 16 patients with ataxia-telangiectasia. No relation to age or to the level of IgG, IgM or IgD was found. Nine out of 11 patients with IgE and IgA deficiency ...